Alzheimer's disease drug development pipeline: 2020
Alzheimer s & Dementia Translational Research & Clinical Interventions2020Vol. 6(1), pp. e12050–e12050
Citations Over TimeTop 1% of 2020 papers
Abstract
The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs. Review of clinical trials over the past 5 years show that there is progressive emphasis on non-amyloid targets, including candidate treatments for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions. There has been a marked growth in repurposed agents in the pipeline.
Related Papers
- → Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups(2024)3 cited
- Me-too drug,me-better drug and me-new drug in drug R&D(2009)
- → People's Drug Guide to Deadly Drug Interactions Focuses on Drug/Drug, Drug/Food, and Drug/Vitamin Interactions(1998)
- → Delay Between Drug Action, Drug Effect and Final Drug Exposure(2022)